Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: Results from a randomized, double-blind, controlled trial

Pediatric Diabetes

Volumn 9, Issue 6, 2008, Pages 554-560

  Danne, Thomas ^a   Datz, Nicolin ^a   Endahl, Lars ^b   Haahr, Hanne ^b   Nestoris, Claudia ^a   Westergaard, Lisbet ^b   Fjording, Marianne Scheel ^b   Kordonouri, Olga ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Insulin detemir; Insulin glargine; Pediatric; Ttype 1 diabetes; Within subject variability

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; NEUTRAL INSULIN;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTHERMIA; HYPOGLYCEMIA; INJECTION SITE DISCOMFORT; INSULIN DEPENDENT DIABETES MELLITUS; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SYNCOPE; THROMBOPHLEBITIS;

ADOLESCENT; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN; MALE;

EID: 56649117255     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2008.00443.x     Document Type: Article

References (28)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
2. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994: 125: 177-188.
3. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001: 139: 804-812.
4. Brownlee M, Hirsch IB. Glycemic variability: A hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006: 295: 1707-1708.
5. Danne T, Becker D. Paediatric diabetes: Achieving practical, effective insulin therapy in type 1 and type 2 diabetes. Acta Paediatr 2007: 96: 1560-1570.
6. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007: 24: 27-34.
7. Chase HP, Dixon B, Pearson J et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 2003: 143: 737-740.
8. Havelund S, Plum A, Ribel U et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004: 21: 1498-1504.
9. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000: 23: 644-649.
10. Heise T, Nosek L, Rønn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004: 53: 1614-1620.
11. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007: 9: 290-299.
12. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000: 159: 483-488.
13. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human patients, 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 and last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly. Washington, 2002.
14. Pieber TR, Treichel HC, Hompesch B et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007: 24: 635-642.
15. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007: 9: 648-659.
16. Kølendorf K, Bojsen J, Deckert T. Clinical factors influencing the absorption of 125 I-NPH insulin in diabetic patients. Horm Metab Res 1983: 15: 274-278.
17. Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003: 26: 3087-3092.
18. Heller S, Olsen KJ, Draeger E. Within-person variation in fasting blood glucose is correlated to incidence of hypoglycemia in people with type 1 diabetes treated with insulin detemir and NPH. Diabetes 2004: 53 (Suppl. 2): A486-A487.
19. Danne T, Weber B, Hartmann R, Enders I, Burger W, Hovener G. Long-term glycemic control has a nonlinear association to the frequency of background retinopathy in adolescents with diabetes. Follow-up of the Berlin Retinopathy Study. Diabetes Care 1994: 17: 1390-1396.
20. Wilson DM, Kollman C. Relationship of A1C to glucose concentrations in children with type 1 diabetes: Assessments by high-frequency glucose determinations by sensors. Diabetes Care 2008: 31: 381-385.
21. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995: 44: 968-983.
22. Shalitin S, Phillip M. The role of new technologies in treating children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2007: 8 (Suppl. 6): 72-79.
23. Donaghue KC, Chiarelli F, Trotta D, Allgrove J, hl-Jorgensen K. ISPAD clinical practice consensus guidelines 2006-2007. Microvascular and macrovascular complications. Pediatr Diabetes 2007: 8: 163-170.
24. Mortensen HB, Robertson KJ, Aanstoot HJ et al. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidore Study Group on Childhood Diabetes. Diabet Med 1998: 15: 752-759.
25. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970: 19: 644-655.
26. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006: 295: 1688-1697.
27. McDonnell CM, Northam EA, Donath SM, Werther GA, Cameron FJ. Hyperglycemia and externalizing behavior in children with type 1 diabetes. Diabetes Care 2007: 30: 2211-2215.
28. Danne T, Lange K, Kordonouri O. New developments in the treatment of type 1 diabetes in children. Arch Dis Child 2007: 92: 1015-1019.